JAMA 2013 Oct 9
Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial.
Related Questions
The patient had minimal to no response to neoadjuvant therapy.
New answer by Medical Oncologist at Dana-Farber Cancer Institute (February 15, 2019)
We have debated this among our disease group. In general we have discounted the pathologic determination of response, and continued with adjuvant FOLFIRINOX despite the discou...